News | Hypertension | February 13, 2017

FDA Grants Expedited Access Pathway for MobiusHD to Treat Resistant Hypertension

EAP program designed to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments

February 13, 2017 — Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD device for the treatment of resistant hypertension.

VDI was also one of only nine companies chosen for the FDA’s Early Feasibility Study Investigational Device Exemptions (IDE) Pilot Program in 2012. The Pilot Program enables companies to conduct smaller-scale studies under the guidance of the FDA in the United States in order to meet the requirements for an earlier pathway toward approval.

The EAP program is a focused initiative, recently launched by FDA, to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments. The program was designed for certain medical devices that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases or conditions, such as resistant hypertension, that may be subject to premarket approval applications.

The MobiusHD System, a minimally-invasive system for the treatment of resistant hypertension, capitalizes on the ability of the body’s baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby amplify the body’s natural response to lower blood pressure through vasodilation.

“Among the benefits of the technology are that it may reduce ambulatory blood pressure in resistant hypertension patients who have not benefited from other device or drug based treatments,” said Prof. Brian Williams, co-principal investigator of the CALM II worldwide clinical trial, and NIHR University College London Hospitals Biomedical Research Centre Director. “The Mobius HD technology may provide an important solution for those patients. We are enthusiastic about the product’s potential as we have seen tremendous results in early studies in the U.S. and Europe.”

“In clinical practice, we regularly observe that despite multiple treatment modalities, many patients are still not responding adequately to therapy, whether it be lifestyle changes, multiple drug therapy, or the combination of each. This lack of response significantly increases their risk of further complications,” said Gregg Stone, M.D., co-principal investigator of the CALM II worldwide clinical trial and director of cardiovascular research and education for Columbia University Medical Center/New York-Presbyterian Hospital and co-director of medical research and education at the Cardiovascular Research Foundation.

“The EAP Designation for the MobiusHD device comes at a critical time for hypertension physicians, who are actively looking for treatment options for patients who are not adequately managed with current guideline-directed therapies,” said George Bakris, M.D., chairman of the worldwide CALM II clinical trial hypertension committee and director, ASH Comprehensive Hypertension Center, The University of Chicago School of Medicine.

For more information: www.vasculardynamics.com

Related Content

Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems hghlighted new features of its Trinias Interventional X-ray line at the America College of C
Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve ar
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
Stroke2prevent Receives FDA 510(k) Clearance for A-View
Technology | Ultrasound Transesophageal echo (TEE)| June 20, 2017
June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S.
IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| June 15, 2017
Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke Univer
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Overlay Init